

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Paul O. Zamora
Serial No.: 10/684,022
Filed: October 10, 2003
Title: Bioactive Medical Films

Examiner: Unknown
Group Art Unit: 1623
Docket: 30817-1012
Conf. No. 5302

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the referenced materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record.

Pursuant to 37 C.F.R. § 1.97(c)(1) and 37 C.F.R. § 1.97(e)(1), Applicant states that each item of information contained in the Supplemental Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Supplemental Information Disclosure Statement.

It is believed that no fee or statement is required with the Supplemental Information Disclosure Statement. However, if a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 13-4213 in order to have this Supplemental Information Disclosure Statement considered.

The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Applicant has not included copies of any US Patents or Published Applications cited with this submission. Should the Office require copies to be provided, Applicant respectfully requests that notice of such requirement be directed to Applicant's below-signed representative. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

Respectfully submitted,

Date 5-5-07

By


Jareen Vilven, Reg. No. 47,156

Peacock Myers, P.C.
P.O. Box 26927
Albuquerque, New Mexico 87125-6927
505 998 6130
Customer No. 05179

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Serial No :10/684,022

Filing Date: October 10, 2003

Title: Bioactive Medical Films

Page 2

Dkt. 30817-1012

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being filed electronically with the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 31st day of May, 2007.



Susan Wilkes, Paralegal

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

	Complete if Known
Application Number	10/684,022
Filing Date	October 10, 2003
First Named Inventor	Zamora, Paul
Art Unit	1623
Examiner Name	MAIER, Leigh C

Sheet

1

of

1

Attorney Docket No: 30817-1012

US PATENT DOCUMENTS

Examiner Initials*	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Filing Date If Appropriate
		US-5069899	12/03/1991	Whitbourne, Richard J.	11/02/1989

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	T ²
--------------------	---------	-------------------------	------------------	---	----------------

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		COX, M.D., DAVID A., et al., "Effect of Local Delivery of Heparin and Methotrexate on Neointimal Proliferation in Stented Porcine Coronary Arteries", <u>Coronary Artery Disease, Current Science, Vol. 3, (1992),237-248</u>	
		EDELMAN, ELAZER R., et al., "Basic Fibroblast Growth Factor Enhances the Coupling of Intimal Hyperplasia and Proliferation of Vasa Vasorum in Injured Rat Arteries", <u>J. Clin. Invest., Vol. 89, (02/1992),465-473</u>	
		KSANDER, GEORGE A., et al., "Exogenous Transforming Growth Factor-Beta 2 Enhances Connective Tissue formation and Wound Strength in Guinea Pig Dermal Wounds Healing by Secondary Intent", <u>Ann. Surg., (03/1990),288-294</u>	
		SELLKE, FRANK W., "Therapeutic Angiogenesis with Basic Fibroblast Growth Factor: Technique and Early Results", <u>Ann. Thorac Surg 1998;65:1540-4, (1988),1540-1544</u>	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO 1449)

*EXAMINER Initial if reference directed to, whether or not citation is in conformance and not overruled. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.